Lin, S., Kennedy, N., Saifuddin, A., Sandoval, D., Reynolds, C., Seoane, R., Kottoor, S., Pieper, F., Lin, K., Butler, D., Chanchlani, N., Nice, R., Chee, D., Bewshea, C., Janjua, M., McDonald, T., Sebastian, S., Alexander, J., Constable, L., Lee, J., Murray, C., Hart, A., Irving, P., Jones, G., Kok, K., Lamb, Christopher A., Lees, C., Altmann, D., Boyton, R., Goodhand, J., Powell, N., Ahmad, T. & study, C. 2022, 'Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab', Nature Communications, 13, article no: 1379. https://doi.org/10.1038/s41467-022-28517-z